Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 21, 2026 at 12:25 AM ET · reviewed against 9 wire stories
AMYLYX PHARMACEUTICA (AMLX) is drawing unusual attention today. Our newswire has captured 9 stories on AMLX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why AMLX stock is moving today
Amylyx Pharmaceuticals Inc. stock is moving higher today, with shares reaching a fresh 52-week high. The stock has gained 67.8% over the past eight trading sessions and is now trading at $39.66. The move follows a series of developments, including an upsized $500 million public offering priced at $35.50 per share for 14.09 million shares. The underwriters also have the option to purchase an additional 2.11 million shares. The offering is expected to close on or about August 21 and is intended to fund the company’s pipeline growth and the launch of Avexitide, its treatment candidate for post-bariatric hypoglycemia.
What Happened
Amylyx Pharmaceuticals announced the pricing of the upsized offering on August 20, 2026, following the filing of an 8-K with the SEC. The offering includes a 14.1 million share secondary priced at $35.50 per share. The company has also secured an underwriting agreement with a lead underwriter, though the name of the underwriter is not disclosed in the provided facts. The capital raised is expected to support ongoing research and development and the commercialization of Avexitide, which has shown strong results in phase 3 clinical trials.
What The Data Shows
The stock has printed 15 fresh 52-week highs on August 21, indicating strong retail and institutional interest. Over the past 8 trading sessions, the stock has surged from $23.63 to $39.66. Insiders have been active recently, with one insider selling $539,000 worth of shares in the past 90 days. The company remains unprofitable, with a trailing twelve-month revenue decline of 100.3% and a negative EPS of -1.43. The market cap stands at $3.9 billion, and the stock is currently trading near its 52-week high of $39.07.
What To Watch
Investors should monitor the closing of the public offering on or about August 21. The company has not announced an earnings date, so coverage breadth and analyst sentiment will be key to watch in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AMLX · Aug 21 session (5-min) · -1.66% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 9 stories · 45/100 bearish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
23d agoTipRanksBEARISH 24General
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide
Amylyx Pharmaceuticals Inc ( ($AMLX) ) just unveiled an announcement. On August 19, 2026, Amylyx Pharmaceuticals Inc. entered into an underwriting agreement with a ...
23d agoSEC 8-KNEUTRAL 50General
Amylyx Pharmaceuticals, Inc. (AMLX) files 8-K
Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
24d agoMarketChameleonBEARISH 28General
Amylyx Upsizes to $500 Million Public Offering: Targeting Pipeline Growth and Avexitide Launch
August 20, 2026
Amylyx Pharmaceuticals has announced an upsized $500 million underwritten public offering, marking a major capital infusion ahead of potential commercial advances and continued R&D. The new funds signal confidence in the expansion of avexitide and other investigational treatments, with key market implications.
24d agoThe FlyBEARISH 28General
Amylyx 14.1M share Secondary priced at $35.50
24d agoSeeking AlphaBEARISH 24General
Amylyx Pharmaceuticals prices upsized $500M public offering of common stock
Amylyx Pharmaceuticals (AMLX) announced the pricing of an upsized underwritten public offering of 14.09M shares of common stock at $35.50 per share. The company also granted underwriters a 30-day option to buy up to an additional 2.11M shares.
24d agoStockTitanBEARISH 26General
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
The offering covers 14.09 million shares at $35.50 each; underwriters can buy up to 2.11 million more, and closing is expected on or about Aug. 21.
25d agoYahoo TopBULLISH 78Product/PR
Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical studies, paving the way for its looming commercialization. In intra-day trading, the stock surged to a record of $35.39 before trimming a few cents to end the session […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →